Drug metabolism and personalized therapy最新文献

'Pharmacogenetics, health and ethnicity in Latin American populations' call for the "Dr José María Cantú Award 2024".

Drug metabolism and personalized therapy Pub Date : 2025-01-02 DOI: 10.1515/dmpt-2024-0091

José Elias Garcia-Ortiz, Ingrid Fricke, Humberto Fariñas, Alejandro Gaviño-Vergara, Alejandra Camacho-Molina, Marcela Gálvez, José Polo-García, Encarna Guillén-Navarro, Adrián Llerena Ruiz

引用次数: 0

Molecular docking and in vitro evaluation of glucosamine sulfate targeting MMP-3, MMP-9, and IL-4 for potential osteoarthritis treatment.

Drug metabolism and personalized therapy Pub Date : 2024-12-19 DOI: 10.1515/dmpt-2024-0067

Venkataramanan Srinivasan, Selvaraj Kunjiappan, Ponnusamy Palanisamy

{"title":"Molecular docking and in vitro evaluation of glucosamine sulfate targeting MMP-3, MMP-9, and IL-4 for potential osteoarthritis treatment.","authors":"Venkataramanan Srinivasan, Selvaraj Kunjiappan, Ponnusamy Palanisamy","doi":"10.1515/dmpt-2024-0067","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0067","url":null,"abstract":"Objectives: This study intended to investigate the potential of glucosamine sulfate (GS) as an inhibitor of genes involved in osteoarthritis (OA) development. Despite GS is often used for OA treatment due to its cartilage preservation and minimum side effects, the molecular mechanism behind its interactions remains unknown.Methods: Molecular docking was conducted to analyze the interactions between glucosamine sulfate and genes associated with OA such as matrix metalloproteinase-3 (MMP-3), MMP-9, and interleukin-4 (IL-4). Additionally, a cell viability assay using RAW 264.7 cells was performed to evaluate the toxicity of glucosamine sulfate at various concentrations.Results: Molecular docking results revealed that glucosamine sulfate has a good binding affinity and stable interactions with MMP-3, MMP-9, and IL-4, indicating that it may have inhibitory effects on targeted genes. Nevertheless, the cell viability assay analysis demonstrated that glucosamine sulfate had considerable toxic effects in RAW 264.7 cells at highest concentrations.Conclusions: Glucosamine sulfate exhibited stable molecular interactions with genes associated to OA development. However, GS toxicity at high concentrations necessitates future research studies to optimize dosing and assess its therapeutic safety in OA treatment.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prolonged post-operative hydrocodone usage due to psychotropic drug interaction. 精神药物相互作用导致术后长期使用氢可酮。

Drug metabolism and personalized therapy Pub Date : 2024-12-16 DOI: 10.1515/dmpt-2024-0031

Aaron G Whitt, Viana F Karimi, Jeremy T Gaskins, Ruby E Renfrow, Abbey R Roach, Arthur L Malkani, Brandi Hartley, Madhusudhan R Yakkanti, Saeed A Jortani

{"title":"Prolonged post-operative hydrocodone usage due to psychotropic drug interaction.","authors":"Aaron G Whitt, Viana F Karimi, Jeremy T Gaskins, Ruby E Renfrow, Abbey R Roach, Arthur L Malkani, Brandi Hartley, Madhusudhan R Yakkanti, Saeed A Jortani","doi":"10.1515/dmpt-2024-0031","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0031","url":null,"abstract":"Objectives: To explore pain outcomes in patients prescribed hydrocodone and psychotropic medications with or without CYP2D6 inhibition activity.Methods: Patients hospitalized for lower/limited upper extremity injuries who were prescribed hydrocodone alongside a psychotropic medication were considered for this study (n=224). A subset of these patients (n=178) was prescribed a psychotropic medication known to inhibit CYP2D6, while the remainder (n=46) were prescribed psychotropic medications without CYP2D6 inhibition activity. Patient demographics and pain outcomes were collected by electronic health record review and interviews.Results: Patients taking a psychotropic inhibitor of CYP2D6 exhibited longer duration of opioid use post-discharge (median 33 days [IQR 10-99]) compared with patients taking a psychotropic non-inhibitor (4 days [2-20], p<0.001). No significant differences were observed with in-hospital pain outcomes, including total dose of hydrocodone administered, duration of hydrocodone use, pain index scores, and the occurrence of common mild/moderate/severe hydrocodone side effects.Conclusions: Patients prescribed at least one psychotropic inhibitor of CYP2D6 were more likely to continue using hydrocodone for up to 3 months following surgery. Knowledge of these critical drug-drug interactions could enhance clinical practice and improve patient outcomes. This study highlights negative post-operative pain outcomes in patients prescribed hydrocodone alongside a psychotropic inhibitor of CYP2D6. The results of this study indicate that patients taking psychotropic medications that inhibit CYP2D6 are at increased risk for prolonged hydrocodone use following orthopedic surgery.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing tacrolimus therapeutic drug monitoring in Tunisian kidney transplant recipients: exploring the variability in bioavailability and the correlation between pharmacokinetic parameters.

Drug metabolism and personalized therapy Pub Date : 2024-12-16 DOI: 10.1515/dmpt-2024-0043

Ghaith Aloui, Rym Charfi, Mouna Daldoul, Syrine Ben Hammamia, Mouna Ben Sassi, Mohamed Zouari, Hanene Eljeberi, Riadh Daghfous, Emna Gaies, Sameh Trabesli

{"title":"Optimizing tacrolimus therapeutic drug monitoring in Tunisian kidney transplant recipients: exploring the variability in bioavailability and the correlation between pharmacokinetic parameters.","authors":"Ghaith Aloui, Rym Charfi, Mouna Daldoul, Syrine Ben Hammamia, Mouna Ben Sassi, Mohamed Zouari, Hanene Eljeberi, Riadh Daghfous, Emna Gaies, Sameh Trabesli","doi":"10.1515/dmpt-2024-0043","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0043","url":null,"abstract":"Objectives: While the existing literature extensively covers the topic of tacrolimus variability, it remains crucial to gather data that are tailored to the Tunisian population. Our primary goal was to assess the variability in tacrolimus bioavailability using the Cp(0)/weight dosage ratio in Tunisian kidney transplant patients. We also aimed to determine the correlations between blood trough level (Cp(0)) and the area under the concentration-time curve (AUC0-12 h) in this cohort.Methods: This retrospective study included patients treated with oral tacrolimus for the prevention of organ rejection between 2009 and 2023. The correlation between parameters was analyzed through a Pearson coefficient and a regression model. We assessed the inter- and intraindividual variability by calculating the coefficient of variation for patients with at least three samples.Results: Analysis of 2,124 samples revealed a weak correlation (R=0.121) between Cp(0) and weight dosage. We found that 79.3 % of patients exhibited high variability in the Cp(0)/weight dosage ratio. A strong correlation (R=0.797) was found between Cp(0) and the AUC0-12 h. We also found that 47.6 % of patients showed high variability in the AUC0-12 h/Cp(0) ratio.Conclusions: This study underscores the necessity for individualized therapeutic drug monitoring in Tunisian kidney transplant recipients due to the high variability in the Cp(0)/weight dosage ratio. The AUC0-12 h/Cp(0) ratio is proposed as a more consistent parameter for therapeutic drug monitoring, offering potential improvements in tacrolimus therapy management.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of metformin on exercise capacity in treatment naïve type 2 diabetes patients. 二甲双胍对初次接受治疗的 2 型糖尿病患者运动能力的影响。

Drug metabolism and personalized therapy Pub Date : 2024-12-16 DOI: 10.1515/dmpt-2024-0049

Vikneswaran Gunaseelan, Sandhiya Selvarajan, Sadishkumar Kamalanathan, Tamilarasu Kadhiravan, Shravan Venkatraman

{"title":"Effect of metformin on exercise capacity in treatment naïve type 2 diabetes patients.","authors":"Vikneswaran Gunaseelan, Sandhiya Selvarajan, Sadishkumar Kamalanathan, Tamilarasu Kadhiravan, Shravan Venkatraman","doi":"10.1515/dmpt-2024-0049","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0049","url":null,"abstract":"Objectives: Exercise capacity is decreased in diabetes mellitus due to impaired insulin sensitivity, endothelial dysfunction and mitochondrial dysfunction. The aim of the study was to evaluate the effect of metformin on exercise capacity in treatment naïve patients with type 2 diabetes mellitus.Methods: Newly diagnosed type 2 diabetes mellitus patients were tested for baseline insulin resistance and exercise capacity, before starting on metformin. Exercise capacity was measured by incremental exercise testing in treadmill (ZAN 600 CPET system) using modified Bruce protocol at baseline, 6 weeks and 12 weeks following metformin therapy.Results: A total of 33 treatment naïve type 2 diabetes patients were enrolled of which 19 patients completed the study. There was no significant change in any of the exercise capacity parameters at the end of 12 weeks of metformin. Nevertheless, there was a significant improvement in VO2/kg among those with insulin resistance as compared to those without insulin resistance.Conclusions: Metformin monotherapy did not produce any change in exercise capacity in treatment naïve type 2 diabetes patients. However, a significant fall in exercise capacity (VO2/kg) was observed in patients without insulin resistance as compared to those with insulin resistance at the end of 12 weeks of metformin therapy.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CYP2C19 genotype-phenotype correlation: current insights and unanswered questions.

Drug metabolism and personalized therapy Pub Date : 2024-12-13 DOI: 10.1515/dmpt-2024-0093

Nadine de Godoy Torso, Fernanda Rodrigues-Soares, Catalina Altamirano, Ronald Ramírez-Roa, Martha Sosa-Macías, Carlos Galavíz-Hernández, Enrique Terán, Eva Peñas-LLedó, Pedro Dorado, Adrián LLerena

引用次数: 0

UHPLC-MS/MS standardized extract of Vernonia amygdalina leaf inhibits CYP2C9 and CYP3A4 activities in hepatic cells of control and streptozotocin-induced diabetic rats.

Drug metabolism and personalized therapy Pub Date : 2024-12-11 DOI: 10.1515/dmpt-2024-0005

Bassel Al Sabbagh, Vijayaraj Kumar Palanirajan, Yik-Ling Chew, Jin Han Chin, Mariam Ahmad, Gabriel Akyirem Akowuah

{"title":"UHPLC-MS/MS standardized extract of Vernonia amygdalina leaf inhibits CYP2C9 and CYP3A4 activities in hepatic cells of control and streptozotocin-induced diabetic rats.","authors":"Bassel Al Sabbagh, Vijayaraj Kumar Palanirajan, Yik-Ling Chew, Jin Han Chin, Mariam Ahmad, Gabriel Akyirem Akowuah","doi":"10.1515/dmpt-2024-0005","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0005","url":null,"abstract":"Objectives: Vernonia amygdalina Del. is a perennial tropical shrub from Asteraceae. The fresh leaf of V. amygdalina is consumed as a vegetable due to its medicinal and nutritional properties. The present study focused on the quantification of bioactive compounds, luteolin-7-O-glucoside, luteolin-7-O-glucuronide, and 1,5-O-dicaffeoylquinic acid from aqueous leaf extract of V. amygdalina. The study also aims to investigate the effects of the aqueous leaf extract of V. amygdalina on cytochrome P450 2C9 (CYP2C9), and cytochrome P450 3A4 (CYP3A4) in hepatic cells of control and diabetic rats.Methods: The quantification of the bioactive compounds was conducted using ultra-high-performance liquid chromatography multiple reactions monitoring tandem mass spectrometry (UHPLC-MS/MS-MRM) technique. The effect of the extract on CYP2C9 and CYP3A4 activities was determined using a fluorometric screening kit according to the manufacturer's instructions.Results: The three bioactive compounds were detected and quantified in the aqueous leaf extract. Results showed that the content of luteolin-7-O-glucuronide (47 μg/mg) was the highest followed by luteolin-7-O-glucoside (3.5 μg/mg) and 1,5-O-dicaffeoylquinic acid (1.07 μg/mg). The extract showed an inhibitory effect on CYP3A4 and CYP2C9 enzyme activities in control and diabetic rats.Conclusions: The UHPLC-MS/MS-MRM method is sensitive and reliable for the quality control of V. amygdalina leaf extract. The inhibitory effect of the extract suggests that concomitant use of V. amygdalina leaf preparations with conventional drugs metabolized and eliminated from the body by CYP3A4 and CYP2C9 enzymes may lead to possible interaction.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives. 西班牙在临床实践中实施药物遗传学的现状：从地区到国家的举措。

Drug metabolism and personalized therapy Pub Date : 2024-11-11 DOI: 10.1515/dmpt-2024-0042

Maria Apellaniz-Ruiz, Jordi Barrachina, Paula Castro-Sanchez, Ana Comes-Raga, Xandra García-González, Almudena Gil-Rodriguez, Elixabet Lopez-Lopez, Olalla Maroñas, Rocío Morón, Javier Muriel, Gladys G Olivera, Pau Riera, Miriam Saiz-Rodríguez, Sara Salvador-Martín, Carla Sans-Pola, Hugo Tejera-Pérez, Alejandro Velasco-Ruiz, Zoraida Verde, Daniel Wang, Ana E Rodríguez-Vicente, Rocio Nunez-Torres

{"title":"Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives.","authors":"Maria Apellaniz-Ruiz, Jordi Barrachina, Paula Castro-Sanchez, Ana Comes-Raga, Xandra García-González, Almudena Gil-Rodriguez, Elixabet Lopez-Lopez, Olalla Maroñas, Rocío Morón, Javier Muriel, Gladys G Olivera, Pau Riera, Miriam Saiz-Rodríguez, Sara Salvador-Martín, Carla Sans-Pola, Hugo Tejera-Pérez, Alejandro Velasco-Ruiz, Zoraida Verde, Daniel Wang, Ana E Rodríguez-Vicente, Rocio Nunez-Torres","doi":"10.1515/dmpt-2024-0042","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0042","url":null,"abstract":"Introduction: Pharmacogenetics (PGx) has the potential to improve patient care, allowing to transform medical interventions by providing personalized therapeutic strategies. Scientific evidence supports the use of PGx in clinical practice and international organizations are developing clinical guidelines to facilitate the utilization of PGx testing. However, clinical implementation of PGx is limited and unequal worldwide.Content: This review summarizes regional and national Spanish initiatives to implement PGx in the clinical practice.Summary and outlook: Diverse strategies to implement PGx in healthcare are applied across countries or even in the different regions of a specific country. Such was the case of Spain, a European country with 17 Autonomous Regions and two Autonomous Cities, each one with capacity to manage their own healthcare systems. Nevertheless, during the past years, many initiatives and strategies have been launched in Spain to develop different aspects of PGx. Importantly, the National Healthcare System has approved a PGx testing catalogue. This review highlights the crucial work and efforts of scientific societies (like the Spanish Society of Pharmacogenetics and Pharmacogenomics), of experts in PGx, of healthcare providers and of governmental parties in the implementation of PGx to personalize patient therapy, focused in Spain.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of a polyherbal formulation in the management of Escherichia coli urinary tract infection. 治疗大肠杆菌尿路感染的多草药配方的有效性和安全性。

Drug metabolism and personalized therapy Pub Date : 2024-11-11 DOI: 10.1515/dmpt-2024-0070

Almas Qureshi, Rais Ur Rahman, Yasmeen Shamsi

{"title":"Efficacy and safety of a polyherbal formulation in the management of Escherichia coli urinary tract infection.","authors":"Almas Qureshi, Rais Ur Rahman, Yasmeen Shamsi","doi":"10.1515/dmpt-2024-0070","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0070","url":null,"abstract":"Objectives: Urinary tract infection (UTI) is one of the most frequent reasons for prescribing antibiotics. Escherichia coli implicated in 75-90 % cases of UTI is becoming increasingly resistant to antibiotics. Finding alternative therapeutic agent for this infection is critical, for which herbal drugs may be an option. In Unani medicine, urinary tract infection (Ṭa'diya Majra-i-Bawl) is treated with herbal drugs possessing Da'fe Ufoonat (antiseptic), Muhallilat (anti-inflammatory) and Mudirrat (diuretic) properties. Polyherbal formulations of such drugs are expected to be beneficial in treating Escherichia coli infection. The aim of the study was to assess the efficacy and safety of a Unani polyherbal formulation aimed to develop a safe and efficacious drug for the treatment of urinary tract infection (Ṭa'diya Majra-i-Bawl) caused by Escherichia coli.Methods: This open-label, single armed clinical study was conducted on patients with clinical signs and symptoms of UTI and positive urine culture for E. coli. Patients were treated with the polyherbal formulation consisting of 50 % hydro-alcoholic extracts of Khar Khasak (Tribulus terrestris), Bhui Amla (Phyllanthus niruri), Kabab Cheeni (Piper cubeba), Beekh -i-Kasni (Cichorium intybus), Beekh-i-Karafs (Apium graveolens), Asl-us-Soos (Glycyrrhiza glabra), and Giloy (Tinospora cordifolia) in a dose of one capsule (500 mg) thrice a day orally with plain water for 42 days.Results: Maximum (83 %) urine cultures turned out negative for E. coli after the completion of therapy.Conclusions: Polyherbal Unani formulation was found to be very effective for the treatment of Urinary tract infection. Clinical and microbiological cure was achieved in maximum number of patients and drug was very well tolerated without any adverse/side effect.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the therapeutic potential and personalized therapy of testosterone: a comprehensive review. 挖掘睾酮的治疗潜力和个性化疗法：全面综述。

Drug metabolism and personalized therapy Pub Date : 2024-11-06 DOI: 10.1515/dmpt-2024-0035

Aditya V Reddy, Ramasamy Kesavan, Rajendran Priyadharsini, Reka Deva

{"title":"Unlocking the therapeutic potential and personalized therapy of testosterone: a comprehensive review.","authors":"Aditya V Reddy, Ramasamy Kesavan, Rajendran Priyadharsini, Reka Deva","doi":"10.1515/dmpt-2024-0035","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0035","url":null,"abstract":"Introduction: Testosterone, the primary male sex hormone, orchestrates various physiological processes including sex differentiation, development of male characteristics, sperm production, and fertility. Its synthesis primarily occurs in Leydig cells within the testes, with smaller contributions from the ovaries and adrenal glands, all derived from cholesterol. Current therapeutic use of testosterone is mainly confined to treating hypergonadotropic hypogonadism, with limited off-label usage for augmenting muscle growth.Content: This review delves into numerous studies investigating testosterone's therapeutic potential across various medical conditions as depicted in the figure given below.Summary: Of all the studies in this review, which show a positive therapeutic result by using testosterone, the most promising areas of potential usage of testosterone are anxiety and diabetes mellitus, followed by obesity and depression.Outlook: By the medium if this study, we want to not only enlist the various potential therapeutic uses of testosterone, but also promote a optimal hormonal balance, which can lead to prevention and/or better treatment outcomes for the mentioned diseases.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0